Volunteers and community spirit build momentum behind parkrun

Posted on Thursday, September 25, 2014


Volunteers and community spirit build momentum behind parkrun

By Mitch Phillips LONDON (Reuters) - Keen to get a regular Saturday fix of 5km runs under the parkrun banner but finding himself some distance from his nearest event, Gary O'Leary went for the obvious solution -- start one on his doorstep. So, on Oct. 11, a week after parkrun celebrates its 10th anniversary, Panshanger parkrun, near Hertford, north of London, will become around the 290th UK adult event. It is hard to be exact, such is the speed of expansion, with two new events taking place each week in the UK plus a rash of junior 2km events on Sundays, and a growing number of both worldwide. ...

Health benefits of parkrun stretch well beyond the physical

Participants take part in a parkrun event at Bushy Park in LondonBy Health and Science Correspondent Kate Kelland LONDON (Reuters) - The thousands of Britons who take to their local green space each week for a mass five kilometre parkrun can expect to reap health benefits well beyond losing a few pounds and lowering their blood pressure. Scientists who have studied the mass participation events, which from a small start in London 10 years ago next week have grown to attract some 70,000 runners a week worldwide, say their effect on psychological and physical health is starting to show. ...



ValueAct returns to Valeant board, plans to raise stake

The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, QuebecBy Caroline Humer and Bill Berkrot (Reuters) - Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company. Valeant shares rose more than 3 percent. ValueAct Chief Executive Officer Jeffrey Ubben said in a statement that once he is on the board, he would work with Valeant on its $53 billion acquisition of Allergan, a deal whose certainty he has previously questioned. ...







{ 0 comments... read them below or add one }